Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Jun 11, 2019
A much-publicized report by the World Health Organization advocates that the price of cancer treatments are excessive. However, its analysis contains significant biases that drastically over-estimates the revenues multiple over research and development (R&D) costs, according to a new issue brief from the Center for Medical Economics and Innovation at the non-partisan Pacific Research Institute. Download a copy of the brief at www.medecon.org.